Stellar Biotechnologies Reports Second Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights

PORT HUENEME, CA--(Marketwired - May 9, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") ( NASDAQ : SBOT ), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announces its financial results for its second fiscal quarter ended March 31, 2016.

"Stellar delivered another quarter with strong operational results, once again increasing sales over previous periods while demonstrating careful management of resources and projects," said Frank Oakes, President and Chief Executive Officer of Stellar Biotechnologies, Inc. "The increased interest in Stellar KLH™ is a direct reflection of the growing pipeline of active immunotherapies using KLH, and recognition for Stellar's value proposition which is our ability to deliver scalable supplies of GMP grade KLH product. We are continuing to work closely with current and prospective customers to ensure long-term support of their immunotherapy programs."

Second Quarter and Six Months Ended March 31, 2016 Financial Results:

Revenues: Stellar generated total revenues of $326,335 and $814,495 for the second quarter and six months ended March 31, 2016, compared to $187,627 and $400,228 for the same periods in 2015, an increase of 74% and 103% respectively. The increase in revenue resulted primarily from an increase in customers and greater product sales volume including sales under supply agreements.

Expenses: Total expenses were $1.42 million and $3.22 million for the second quarter and six months ended March 31, 2016, compared to $1.38 million and $2.92 million for the same periods in 2015. Costs of revenues increased to $348,150 and $745,126 for the second quarter and six months ended March 31, 2016, compared to $309,996 and $487,097 for the same periods in 2015. These costs increased because of higher product sales but did not increase at the same rate as revenues because we have certain indirect manufacturing costs that are incurred regardless of product sales levels. 

Research and development expenses were $309,062 and $597,911 in the second quarter and six months ended March 31, 2016, compared to $281,584 and $700,405 in the same periods in 2015. The changes in R&D expenses were a result of the continued realignment of our focus from internal research and process development to manufacturing our Stellar KLH™ products in response to increased customer demand, partially offset by increased costs related to our aquaculture feasibility assessment in Baja Mexico.

General and administration expenses were $765,066 and $1.87 million for the second quarter and six months ended March 31, 2016, compared to $785,681 and $1.73 million for the same period in 2015. The changes in G&A resulted from a combination of increased corporate expenses, including our Nasdaq listing fees; compensation increases; and increased investor relations activity; partially offset by a reduction in business development travel and decreased share based compensation, which is affected by the timing of option grants and assumptions used in the valuation model.

Net Loss: The net loss for the second quarter ended March 31, 2016 was $861,010, or ($0.10) per basic share, compared to a net loss of $426,164, or ($0.05) per basic share, for the quarter ended March 31, 2015. The net loss for the six months ended March 31, 2016 was $2.49 million, or ($0.30) per basic share, as compared to a net loss of $1.77 million, or ($0.22) per basic share, for the six months ended March 31, 2015. The increase in net loss was primarily due to fluctuations in noncash gain/loss in fair value of warrant liability, partially offset by foreign exchange gains in the second quarter and six months ended March 31, 2016. 

Capital Resources: Working capital was $8.1 million as of March 31, 2016, compared to working capital of $7.49 million as of September 30, 2015. Cash and cash equivalents totaled $5.96 million at March 31, 2016, compared to cash and cash equivalents of $3.96 million at September 30, 2015, which represented an increase of $2.01 million. Our short-term investments totaled approximately $2.0 million at March 31, 2016, compared to short-term investments of $5.02 million at September 30, 2015, which represented a decrease of $3.02 million over the six-month period.

Shareholders' Equity: Stellar had positive shareholders' equity of $8.81 million and approximately 8.45 million shares outstanding as of March 31, 2016, compared to shareholders' equity of $8.0 million and approximately 7.95 million shares outstanding at September 30, 2015. The increase in shareholders' equity was the result of the exercise of warrants during the six-month period, offset by net loss.

Conference Call Information and Webcast Information: Date: Wednesday, May 11, 2016 Time: 1:30 pm ET / 10:30 am PT Conference call dial-in: 1-913-312-1495 Conference call passcode: 3796482 Webcast Link: https://www.webcaster4.com/Webcast/Page/1359/15015

Q&A Submission: Questions for management may be submitted via the chat feature of the live online webcast.

Please log in at least 10 minutes before the start time to ensure timely participation and appropriate web interface platform.

An archived replay version of the conference call will be available approximately two hours after the live call ends through Wednesday, May 25, 2016 at 11:59 PM Eastern Time by dialing (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) and entering passcode 3796482. The webcast replay will be available shortly after the conference call; to review visit the "Investors" section of Stellar's website at: http://ir.stellarbiotechnologies.com/events-calendar .

Stellar Biotechnologies will file its Form 10-Q for the period ending March 31, 2016 with the Securities and Exchange Commission ("SEC") on Tuesday May 10, 2016. To view the Company's filings under Form 20-F, Form 10-K, 10-Q and 8-K, please visit the U.S. SEC website ( www.sec.gov ). To view the Company's filings with the Canadian Securities Administrators ("CSA"), including the Management Discussion and Analysis and related consolidated financial statements, please visit the CSA's SEDAR website ( www.sedar.com ).

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. ( NASDAQ : SBOT ) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org .

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of the Company's or its partners' anticipated results, including in connection with clinical trials; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the B.C. Securities Commission and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.

           
Condensed Interim Consolidated Balance Sheets
(Unaudited - Prepared by Management)
(Expressed in US Dollars)
           
      March 31,   September 30,
      2016   2015
               
Assets:          
  Cash, cash equivalents and short-term investments $ 7,960,889   $ 8,970,674
  Other current assets   754,591     895,945
  Noncurrent assets   713,258     519,308
               
    Total Assets $ 9,428,738   $ 10,385,927
               
Liabilities and Shareholders' Equity:          
  Accounts payable, accrued liabilities and deferred revenue $ 616,097   $ 830,018
  Warrant liability, including current portion   -     1,550,630
  Shareholders' equity   8,812,641     8,005,279
               
    Total Liabilities and Shareholders' Equity $ 9,428,738   $ 10,385,927
               
               
                         
Condensed Interim Consolidated Statements of Operations  
(Unaudited - Prepared by Management)  
(Expressed in US Dollars )  
                         
    Three Months Ended     Six Months Ended  
    March 31,     March 31,     March 31,     March 31,  
    2016     2015     2016     2015  
                                 
Revenues:                              
  Product sales $ 326,335     $ 142,627     $ 782,495     $ 295,288  
  Contract services revenue   -       45,000       32,000       105,000  
                                 
    Total Revenues   326,335       187,627       814,495       400,288  
                                 
Expenses:                              
  Costs of revenues   348,150       309,996       745,126       487,097  
  Research and development   309,062       281,584       597,911       700,405  
  General and administration   765,066       785,681       1,874,755       1,727,834  
                                 
    Total Expenses   1,422,278       1,377,261       3,217,792       2,915,336  
                                 
Other Income (Loss):                              
  Foreign exchange gain (loss)   226,764       (307,546 )     117,636       (468,658 )
  Gain (loss) in fair value of warrant liability   -       1,061,776       (211,956 )     1,201,332  
  Other income   8,169       18,240       14,004       31,533  
                                 
Income tax expense   -       9,000       7,200       18,800  
                                 
Net Loss $ (861,010 )   $ (426,164 )   $ (2,490,813 )   $ (1,769,641 )
                                 
Loss per common share - basic and diluted $ (0.10 )   $ (0.05 )   $ (0.30 )   $ (0.22 )
Weighted average number of common shares outstanding - basic and diluted   8,448,758       7,954,665       8,410,835       7,950,336  
                                 
                                 
               
Condensed Interim Consolidated Statements of Cash Flows  
(Unaudited - Prepared by Management)  
(Expressed in US Dollars )  
               
      Six Months Ended  
      March 31,     March 31,  
      2016     2015  
                   
Cash Flows Used In Operating Activities:              
  Net loss $ (2,490,813 )   $ (1,769,641 )
  Items not affecting cash:              
    Depreciation and amortization   68,732       77,602  
    Share-based payments   167,329       198,927  
    Foreign exchange (gain) loss   (117,636 )     468,658  
    (Gain) loss in fair value of warrant liability   211,956       (1,201,332 )
  Changes in working capital items   (87,094 )     (355,672 )
                   
Net cash used in operating activities   (2,247,526 )     (2,581,458 )
                   
Net cash provided by investing activities   2,752,767       360,080  
                   
Net cash provided by financing activities   1,368,260       28,719  
                   
Effect of exchange rate changes on cash and cash equivalents   132,723       (438,778 )
                   
Net change in cash and cash equivalents   2,006,224       (2,631,437 )
                   
Cash and cash equivalents - beginning of period   3,955,503       8,768,459  
                   
Cash and cash equivalents - end of period $ 5,961,727     $ 6,137,022  
                   

Stellar Biotechnologies Company Contact: Mark A. McPartland Vice President of Corporate Development and Communications Phone: +1 (805) 488-2800 ext. 103 markmcp@stellarbiotech.com www.stellarbiotech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 85

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 47

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 134

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 122

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 57

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 115

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 102

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading

Top 5 Most Recently Viewed Articles

Mining Stocks: Resilience Amid Market Fluctuations and Trends

Updated Category News Views 466

Understanding the Mining Stocks' Performance In recent discussions, subscribers to the Mining Stock Journal have raised an intriguing question: Will a significant decline in the broader market be necessary for mining stocks to continue their upward trajectory? This line of thought seems to resonate with several market analysts, but it warrants a closer look. Mining stocks...

Continue Reading
Goliath Resources Unveils Ambitious 40,000-Meter Drill Campaign

Updated Category News Views 191

Exciting Times for Goliath Resources Goliath Resources is embarking on a groundbreaking journey with its largest drill campaign yet, focusing entirely on the high-grade gold discovery known as Surebet. This campaign aims to cover an impressive 40,000 meters and will utilize nine drilling rigs. The motivation for such an extensive drilling program stems from the...

Continue Reading
Who Will Dominate the Semiconductor Sector in 2024?

Updated Category News Views 137

The Competitive Landscape of Semiconductors The semiconductor industry is currently experiencing fierce competition, with three key players at the forefront: Broadcom Inc (NASDAQ: AVGO), Micron Technology Inc (NASDAQ: MU), and Marvell Technology Inc (NASDAQ: MRVL). By examining the specific strengths and hurdles each company faces, investors can gain valuable insights...

Continue Reading
Goldman Sachs' Recent Options Activity Shows Enthusiasm

Updated Category News Views 228

The Bullish Sentiment Surrounding Goldman Sachs In recent times, major financial players have shown a notable bullish sentiment towards Goldman Sachs Gr (NASDAQ: GS). Our analysis of the options market reveals intriguing insights through 37 distinctive trades surrounding this financial powerhouse. When we look deeper into the trading data, it's noteworthy that...

Continue Reading
Eramet's Strategies for Enhanced Operational Efficiency in 2025

Updated Category News Views 305

Analyzing Eramet's Strategic Direction in 2025 Eramet's commitment to operational efficiency has never been more critical than in 2025, especially after encountering significant pressures during the first half of the year. The company's recent announcements underscore an enhancement in various operational protocols, demonstrating a resilient approach towards addressing...

Continue Reading